Table III.

Antibacterial agents (Aas) susceptibility of Proteus spp. strains (n = 98) isolated from bacteremia.

Aas	Primary bacteremia Aas susceptibility						p*	Secondary bacteremia Aas susceptibility						Total Aas susceptibility
	S		I		R			S		I		R		S		I		R
	n	%	n	%	n	%		n	%	n	%	n	%	n	%	n	%	n	%
AMC	9	22.5	24	60.0	7	17.5	0.4588	16	27.6	28	48.3	14	24.1	25	25.5	52	53.1	21	21.4
TZP	40	100.0	0	0.0	0	0.0	0.1316	54	93.1	0	0.0	4	6.9	94	95.9	0	0.0	4	4.1
CMX	28	70.0	0	0.0	12	30.0	0.6037	45	77.6	0	0.0	13	22.4	73	74.5	0	0.0	25	25.5
CTX	31	77.5	0	0.0	9	22.5	0.3393	46	79.3	0	0.0	12	20.7	77	78.6	0	0.0	21	21.4
CAZ	35	87.5	2	5.0	3	7.5	0.1697	51	87.9	0	0.0	7	12.1	86	87.8	2	2.0	10	10.2
FEP	32	80.0	2	5.0	6	15.0	0.4254	48	82.8	4	6.9	6	10.3	80	81.6	6	6.1	12	12.2
IMP	30	75.0	8	20.0	2	5.0	0.6062	49	84.5	8	13.8	1	1.7	79	80.6	16	16.3	3	3.1
GEN	29	72.5	1	2.5	10	25.0	0.3662	46	79.3	1	1.7	11	19.0	75	76.5	2	2.0	21	21.4
AMK	33	82.5	3	7.5	4	10.0	0.6311	52	89.7	4	6.9	2	3.4	85	86.7	7	7.1	6	6.1
CIP	24	60.0	1	2.5	15	37.5	0.4336	38	65.5	5	8.6	15	25.9	62	63.3	6	6.1	30	30.6
SXT	20	50.0	0	0.0	20	50.0	0.3165	28	48.3	0	0.0	30	51.7	48	49.0	0	0.0	50	51.0

^*chi² test – differences in the susceptibility of Proteus spp. strains isolated from primary and secondary bacteremia S – susceptible, I – intermediate, R – resistant, AMC – amoxicillin + clavulanic acid, TZP – piperacillin with tazobactam, CXM – cefuroxime, CTX – cefotaxime, CAZ – ceftazidime, FEP – cefepime, IMP – imipenem, GEN – gentamicin, AMK – amikacin, CIP – ciprofloxacin, SXT – co-trimoxazole